685513-98-8 Usage
General Description
"1H-Pyrrolo[2,3-b]pyridin-5-ol, 4-chloro-1-[tris(1-methylethyl)silyl]-" is a technical chemical name for a specific compound. It is categorized under the class of organic compounds known as pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyridinones. The structure of the compound shows that it includes a pyrrolopyridine core which is a polycyclic aromatic compound. Also notable within this chemical structure is the organosilicon group, tris(1-methylethyl)silyl, attached to one of the nitrogen atoms in the core structure. This particular group introduces silicon into the compound, which can influence its chemistry and reactivity. Overall, the compound blends characteristics related to both the pyrrolopyridine structure and organosilicon chemistry. Its exact use, however, would depend on the specific context or application.
Check Digit Verification of cas no
The CAS Registry Mumber 685513-98-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,8,5,5,1 and 3 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 685513-98:
(8*6)+(7*8)+(6*5)+(5*5)+(4*1)+(3*3)+(2*9)+(1*8)=198
198 % 10 = 8
So 685513-98-8 is a valid CAS Registry Number.
InChI:InChI=1/C16H25ClN2OSi/c1-10(2)21(11(3)4,12(5)6)19-8-7-13-15(17)14(20)9-18-16(13)19/h7-12,20H,1-6H3
685513-98-8Relevant articles and documents
CHEMICAL COMPOUNDS
-
, (2020/12/01)
The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
